Li Panfeng, Yu Jiang, Hou Wenbin, Li Yiliang. Progress in the application of PET/CT diagnostic drug 68Ga-FAPI-04[J]. Int J Radiat Med Nucl Med, 2024, 48(7): 455-461. DOI: 10.3760/cma.j.cn121381-202303037-00439
Citation: Li Panfeng, Yu Jiang, Hou Wenbin, Li Yiliang. Progress in the application of PET/CT diagnostic drug 68Ga-FAPI-04[J]. Int J Radiat Med Nucl Med, 2024, 48(7): 455-461. DOI: 10.3760/cma.j.cn121381-202303037-00439

Progress in the application of PET/CT diagnostic drug 68Ga-FAPI-04

  • Fibroblast activation protein (FAP) is a type Ⅱ membrane-bound glycoprotein that is overexpressed in fibroblasts of 90% epithelial tumors, wound healing or inflammatory sites, but is low or absent in normal tissues, and is an important target for disease diagnosis and treatment. 68Ga-FAPI-04 is a PET diagnostic drug based on quinoline-based FAP inhibitors, which has shown high specificity and affinity for FAP in patients both in vivo and in vitro, and has received wide attention in basic research and clinical applications. The author reviewed the basic overview of 68Ga-FAPI-04 and its application in various malignant and non-cancerous diseases.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return